Infectious Disease
Sinclair G, Cunningham D, Gupta SK, Richardson D, Reynolds M, Nelson K, Puga A, Garris C. US Healthcare Provider Perspectives on the initiation of cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world study (BEYOND). Poster presented at the 17th Annual ACTHIV 2023 Conference; May 4, 2023. Phoenix, AZ.
Trennery CL, Martin S, Kosa K, Demetriou L, Joshi AV. Patient perceptions of treatment success in uncomplicated urinary tract infection. Poster presented at the IDWeek 2022; October 22, 2022. Washington, DC. [abstract] Open Forum Infect Dis. 2022 Dec; 9(Suppl 2):S917-8. doi: 10.1093/ofid/ofac492.1861
Trennery C, Kosa K, Joshi A, Demetriou L, Martin S. Applying established methods to evaluate the meaningfulness of PRO endpoints to endpoints defined by Clinician-reported Outcomes (ClinROs): an example of uncomplicated Urinary Tract Infection (uUTI). Poster presented at the ISOQOL 29th Annual Conference 2022; October 19, 2022. Prague, Czech Republic. [abstract] Qual Life Res. 2022 Nov 25; 31((Suppl 2)):S132. doi: 10.1007/s11136-022-03257-1
Chan EKH, Williams V, Romano C, Fehnel S, Slagle AF, Stoddard J, Sadoff J, Mayorga M, Lewis S, Yarr S, Ma J, Liu Y, Katz EG, McNulty P, van Dromme I, McQuarrie K. Psychometric evaluation of the symptoms of infection with coronavirus-19 (SIC): results from a cross-sectional study and a phase 3 clinical trial. J Patient Rep Outcomes. 2023 May 17;17(1):45. doi: 10.1186/s41687-023-00581-z
Stempniewicz N, Davenport E, Wang J, Sweeney C. Herpes zoster vaccination in 50-59-year-olds: primary care knowledge and practices. Presented at the National Medical Association ( NMA) 2023 Annual Convention and Scientific Assembly; July 29, 2023. New Orleans, LA.
Ghaswalla P, Hitchens A, Candrilli SD, Carrico J, Hicks KA, Wilson E, Mehta D, Panozzo CA. Prevalence of underlying conditions associated with higher risk for severe RSV, influenza, or COVID-19 in adults in the United States, 2017-2018. Poster presented at the IDWeek 2023; October 12, 2023. Boston, MA.
Grace M, Colosia A, Wolowacz S, Panozzo C, Ghaswalla P. Economic burden of respiratory syncytial virus infection in adults: a systematic literature review. J Med Econ. 2023;26(1):742-59. doi: 10.1080/13696998.2023.2213125
AIMS: Capture the economic and healthcare resource utilization (HCRU) burden in older adults due to respiratory syncytial virus (RSV) infection.
Grace M, Costello J, Colosia A, Wolowacz S, Panozzo CA, Ghaswalla P. Economic and health-related quality of life burden in adults with RSV: a systematic literature review and gap analysis. Poster presented at the 2023 Respiratory Synctial Virus Foundation (RSVVW); February 22, 2023. Lisbon, Portugal.
BACKGROUND: Respiratory syncytial virus (RSV) is a major cause of severe respiratory disease in older adults aged ≥ 65 years and adults with underlying conditions such as chronic heart or lung disease and those with immunocompromising conditions.
Ahmadizar F, Fortuny J, Cid-Royo A, Plana E, Weinrib R, Garcia Esteban R, Boric K, Yefimenko N, Carreras JJ, Urcheguia A, Correcher-Martinez E, Mira-Iglesias A, Swart KMA, van den Berg JM, Overbeek JA, Villalonos F, Bissacco CA, Newbern C, Praet N, Willame C, Sturkenboom M. Safety of the Janssen COVID-19 vaccine (JCOVDEN) using VAC4EU European healthcare data: methods and results of the first study feasibility assessment. Poster presented at the 39th ICPE Annual Conference; August 25, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):189-90. doi: 10.1002/pds.5687
BACKGROUND: As part of the lifecycle benefit-risk assessment of vaccines, a post-authorisation safety study (PASS) using real-world data was required by EMA-PRAC to characterise and evaluate the safety of the JCOVDEN.